The imidazo[1,2-a]pyridine scaffold is recognized as a privileged structure as it represents a
promising area for identification of lead structures towards the discovery of new synthetic drug molecules.
Several commercial drugs such as Zolpidem, Olprinone, Soraprazan and many other compounds
in biological testing and preclinical evaluation, illustrate the wide therapeutic spectrum in this class of
drug scaffolds. The present manuscript represents the assimilation of literature pertaining to medicinal
aspects of this pharmacophore including the structure-activity relationships.
Keywords: Imidazo[1, 2-a]pyridine, SAR, Groebke-Blackburn-Bienayme reaction, Ugi Type, Multicomponent Reaction, N-fused
Rights & PermissionsPrintExport